🇺🇸 FDA
Patent

US 7781404

IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof

granted A61KA61K38/00

Quick answer

US patent 7781404 (IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Aug 19 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Aug 24 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 19 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K38/00